ALLMedicine™ Endocrine Cancers Center
Research & Reviews 48 results
https://doi.org/10.1016/j.amjsurg.2022.10.046
American Journal of Surgery; Manzella A, Laird AM et. al.
Nov 6th, 2022 - •Background: The Affordable Care Act's Medicaid expansion increased insurance coverage and access to care for endocrine cancers, though impact on benign endocrine disease is unknown. •Methods: Patients undergoing operations for benign thyroid, par...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709335
BMC Cancer; Datar S, Cabanillas M et. al.
Dec 4th, 2020 - Thyroid malignancies are among the most common endocrine cancers worldwide. Owing to the angiogenic nature of these malignancies, tyrosine kinase inhibitors (TKIs) are an attractive potential treatment. However, TKIs have been associated with an i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604788
BMJ Case Reports; Pradeep S, Hedne N et. al.
Nov 1st, 2020 - Thyroid cancer is the most common among endocrine cancers. Over 90% of all thyroid malignancies are differentiated thyroid carcinomas (DTC). However, only 2%-13% of DTC present with bone metastasis. Radioactive iodine ablation (RAI) is the treatme...
https://clinicaltrials.gov/ct2/show/NCT04106843
Sep 7th, 2020 - PRIMARY OBJECTIVE: I. Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by Ia. Computed tomography (CT) or Ib. Magnetic resonance imaging (MRI). SECONDARY OBJECTIVES: I. To estimate progression-f...
https://clinicaltrials.gov/ct2/show/NCT03068013
Sep 1st, 2020 - The study is coordinated by the Program on Psycho-Oncology and Palliative Care, University of Ferrara Northern Italy. Another centre from northern Italy will collaborate. The study is designed as a single-blinded randomized-controlled trial with t...
Clinicaltrials.gov 3 results
https://clinicaltrials.gov/ct2/show/NCT04106843
Sep 7th, 2020 - PRIMARY OBJECTIVE: I. Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by Ia. Computed tomography (CT) or Ib. Magnetic resonance imaging (MRI). SECONDARY OBJECTIVES: I. To estimate progression-f...
https://clinicaltrials.gov/ct2/show/NCT03068013
Sep 1st, 2020 - The study is coordinated by the Program on Psycho-Oncology and Palliative Care, University of Ferrara Northern Italy. Another centre from northern Italy will collaborate. The study is designed as a single-blinded randomized-controlled trial with t...
https://clinicaltrials.gov/ct2/show/NCT01794676
Jun 16th, 2017 - Participants will be sent a personal medical questionnaire and family history questionnaire to complete prior to their visit. Participants will meet with a genetic counselor face-to-face for up to 120 minutes to complete a personal and family hist...
News 4 results
https://www.onclive.com/view/dr-burris-discusses-targeting-the-mtor-pathway
Dec 4th, 2020 - Howard A. "Skip" Burris, III, MD, chief medical officer and executive director, Drug Development Program, Sarah Cannon Research Institute in Nashville, Tennessee, discusses successful clinical applications for the inhibition of the mammalian targe...
https://www.onclive.com/view/expert-emphasizes-lack-of-treatment-options-for-medullary-thyroid-cancer
Nov 13th, 2020 - Jochen H. Lorch, MD, MS Though some patients with medullary thyroid cancer (MTC) can live with their disease without progression for long periods of time, the majority will eventually enter a phase in which their cancer becomes much more aggressi...
https://www.mdedge.com/psychiatry/article/177055/bipolar-disorder/lithium/cancer-link-debunked
Bruce Jancin
Oct 12th, 2018 - BARCELONA – A large Swedish national registry study has found no hint of increased cancer risk in bipolar patients on long-term lithium therapy. Bruce Jancin/MDedge News Dr.
https://www.medscape.com/viewarticle/565829_3
Familial Isolated Pituitary Adenomas Apart from familial acromegaly, few studies, none systematic in nature, had been published on other types of familial pituitary tumors unrelated to MEN-1 or CNC. Analyzing the records from our own center beginn...